AstraZeneca Pharma India gets CDSCO Panel Nod to study anti-cancer drug Datopotamab deruxtecan/Rilvegostomig

The purpose of this study is to evaluate the efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

Non-small cell lung cancer (NSCLC) is a disease in which malignant (cancer) cells form in the tissues of the lung.

Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to a potent, exatecan-derived topoisomerase I inhibitor payload via a plasma-stable, selectively cleavable linker.

Rilvegostomig simultaneously targets, binds to and inhibits PD-1 and TIGIT and their downstream signaling pathways. Inhibition of PD-1-mediated signaling may restore immune function through the activation of T-cells and T-cell-mediated immune responses.

At the recent SEC meeting for Oncology held on June 18, 2024, the expert panel reviewed phase 3 clinical study protocol no. D7632C00001 version 1.0 dated 30 October 2023.

After detailed deliberation, the committee recommended the grant of permission to conduct the trial as presented by the firm.

Also Read: CDSCO Panel Approves AstraZeneca pharma's Protocol Amendment proposal to study Anifrolumab